Introduction
============

Tachyplesin is a type of cationic β-hairpin antimicrobial peptide (AMP) discovered from horseshoe crab hemocytes approximately 30 years ago ([@B43]; [@B40]; [@B24]; [@B42]). Though it shows broad-spectrum and potent antimicrobial activity on pathogens, especially multidrug-resistant (MDR) pathogens, clinical application of tachyplesin is precluded by its highly hemolytic effects ([@B51]; [@B5]; [@B35]; [@B12]). More ominously, experimental induction of resistance to tachyplesin was reported due to increased proteolytic activity in *Pseudomonas aeruginosa* ([@B21]). A deep understanding of the unique mechanism of action by which tachyplesin kills bacteria may be helpful to overcome its shortcomings, including hemolysis and susceptibility to proteolysis, and may be helpful for the development of novel antibiotics.

Two models trying to explain how tachyplesin works emerged shortly after it was discovered. One proposed that tachyplesin interacted with lipid membranes and induced enhanced permeability of bacterial membranes, which may contribute to the death of the bacteria ([@B37], [@B38]; [@B45]; [@B23]). The other proposed that the antiparallel beta-sheet structure formed by disulfides helped with tachyplesin binding to DNA and might play roles in bacteria killing ([@B59]). Though the former model seems to be more prevalent, reports concerning this issue are mainly depictions of the physical interactions between this peptide and artificial lipid bilayers, and more biological details are still needed ([@B7], [@B8]). In any case, two conclusions can be drawn from these observations. The first is that compared with membrane rupture activities, the membrane translocation activity of tachyplesin is more relevant to its antimicrobial potential, which is demonstrated by the fact that linear analogs of tachyplesin without disulfide formation could cause more serious membrane disruptions than a cyclic peptide, which also formed pores during the translocation process but showed weaker membrane translocation ability and weaker antimicrobial activity ([@B38], [@B39]; [@B7], [@B8]). The other conclusion is that membrane translocation activity is necessary but not sufficient for tachyplesin to kill bacteria, which is based on the reports that compared to tachyplesin alone, poly(ethylene glycol) (PEG)-grafted (PEGylated) tachyplesin showed similar membrane translocation activity but significantly weakened antimicrobial activity ([@B22]; [@B17]). These phenomena imply that tachyplesin may play an intracellular role.

These speculations have been gradually strengthened by several recent reports. Research using confocal microscopy and flow cytometry to investigate the anti-tumor activities of tachyplesin showed that it induced controlled cell death by promoting apoptosis of the human erythroleukemia cell line K562 at lower concentrations and resulted in cell membrane disruption at higher concentrations ([@B46]). Proteomic profiling of the effects of tachyplesin on glioblastoma multiforme cell line U251 also implied that tachyplesin may cause cell death by affecting intracellular enzymes and by promoting apoptosis ([@B31]). Regarding its antimicrobial effects, confocal microscopy and flow cytometry showed that bacteria died gradually in response to a sublethal concentration of tachyplesin and died instantaneously upon exposure to high concentrations of tachyplesin. Though this process was accompanied by the inactivation of intracellular esterases, no further details were reported ([@B20]).

A systemic view of how bacteria react to antibiotics by omics assay may reflect pathways with which these antibiotics interfere and is helpful to elucidate undefined mechanisms of novel antibiotics, including AMPs ([@B25]; [@B56]; [@B19]; [@B50]; [@B52]). In the present study, we treated MDR clinically isolated pathogens with lethal and sublethal doses of tachyplesin, tested the membrane translocation activity of fluorescein isothiocyanate (FITC)-tagged tachyplesin with confocal microscopy, assessed the membrane rupture activity using DNA-binding fluorescent dye propidium iodide (PI), and further analyzed the differentially expressed RNA-sequencing data with standard bioinformatics analyses, such as Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis. *In vitro* tests, including surface plasmon resonance and enzyme activity assays, molecular docking predictions, and RNA interference, were also performed to confirm the potential targets of tachyplesin identified by RNA sequencing data.

Materials and Methods {#s1}
=====================

Ethics Statement
----------------

The animal experimental procedures were approved by the Ethics Committee of Animal Care and Welfare of the Institute of Medical Biology, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medial College (PUMC) (Permit Number: SYXK (dian) 2010-0007). All efforts were made to minimize animal suffering.

Serum Stability, Cytotoxicity, Membrane Rupture and Translocation Activity
--------------------------------------------------------------------------

These studies were carried out as we previously reported with slight modifications and briefly introduced as follows ([@B33]). Serum stability was assessed with increases over the minimal inhibitory concentration (MIC) of tachyplesin III (KW*C*FRVCYRGICYRK*C*R; cysteines with the same type font formed on disulfide; purity ≥ 95%, synthesized by GL Biochem Co., Ltd, Shanghai, China) on *Escherichia coli* strain DH5α after incubation in serum. Cytotoxicity in different cell lines was assessed using the Cell Proliferation Kit II (XTT) (Roche), and cytotoxicity in hemocytes was evaluated by the increase in the absorbance at 540 nm after peptide incubation. Membrane rupture was indicated by the entrance of the DNA-binding fluorescent dye PI into MDR clinical isolates of *P. aeruginosa* strain 1409. Membrane translocation of N-terminal FITC-conjugated tachyplesin III (purity ≥ 95%, synthesized by GL Biochem Co., Ltd, Shanghai, China) into MDR clinical isolates of *Acinetobacter baumannii* strain 1408 were detected by confocal laser-scanning microscopy.

Transcriptome Analysis
----------------------

The Vitek 32 system (bioMerieux, France) and 16S rDNA sequencing were used to verify the clinical isolates *A. baumannii* 1408, *P. aeruginosa* 1409, *Klebsiella pneumoniae* 5 and *E. coli* 513, which were grown overnight in Luria-Bertani (LB) medium at 37°C with constant shaking at 220 rpm to reach the middle of their logarithmic growth phase. A final concentration of 16 μg/ml tachyplesin III (1×, 2×, 1/2×, and 4× MICs for *A. baumannii* 1408, *P. aeruginosa* 1409, *K. pneumoniae* 5 and *E. coli* 513, respectively) and 32 μg/ml levofloxacin (1×, 2×, 2×, and 1× MICs for *A. baumannii* 1408, *P. aeruginosa* 1409, *K. pneumoniae* 5, and *E. coli* 513, respectively) were added, and the cultures were incubated at 37°C for 30 min. After the addition of 2 volumes of RNAprotect Bacteria Reagent (QIAGEN) to stabilized RNA, samples were vortexed for 5 s, incubated for 5 min at room temperature (15--25°C) and collected by centrifugation at 4°C for 5 min at 4000 *g*.

RNA isolation and sequencing were performed by Novogene Bioinformatics Technology Co., Ltd. (Beijing, China) as previously described ([@B32]). Clean reads were mapped to the corresponding bacterial genomes using Bowtie 2 software ([@B29]). Gene expression was calculated using the FPKM (expected number of fragments per kilobase of transcript sequence per millions of base pairs sequenced) method with HTSeq software (union model) ([@B2]). Differentially expressed genes were selected based on the DESeq R package with Padj values \< 0.05 ([@B1]). KEGG pathway analysis was performed using KOBAS (2.0), and the corrected *p* value cut-off was set at 0.05 ([@B30]).

Verification of *FabG* Transcription Levels by Quantitative Real-Time PCR
-------------------------------------------------------------------------

Quantitative real-time PCR (RT-PCR) was performed following the 2^-ΔΔCT^ method with RNAs from the aforementioned transcriptome analysis ([@B36]; [@B34]). Untreated pathogen strains were used as the calibrator strains, and corresponding ribosomal *rpsL* genes were used as housekeeping reference genes with the primers shown in Supplementary Table [S1](#SM1){ref-type="supplementary-material"} ([@B10]).

RNA Interference (RNAi)
-----------------------

*Pseudomonas aeruginosa* 1409 incubated overnight in LB medium at 37°C were re-incubated under the same conditions to reach an OD600 of 0.5--1.0, put on ice for 15 min to stop growth, washed three times with sterile deionized water and collected by centrifugation at 4°C for 15 min at 4000 × *g*. After washing with sterile 10% glycerol in water (v/v), cells were collected via the aforementioned centrifugation conditions and re-suspended in 10% glycerol in water (v/v) to obtain electrotransformation-competent *P. aeruginosa* cells.

With the RNA oligo pairs shown in Supplementary Table [S2](#SM2){ref-type="supplementary-material"} (GenePharma Co., Ltd, Shanghai, China) targeting *FabG* from *P. aeruginosa*, RNAi was carried out with a GenePulser Xcell system using a 2 mm cuvette with the default settings for *P. aeruginosa* (2.5 kV/cm, 25 μF and 200 Ω). The transformants were either spread onto LB agar plates to calculate the number of bacterial clones or incubated in LB medium at 37°C for 40 min to determine *FabG* transcript levels by RT-PCR using the primers for *P. aeruginosa* shown in Supplementary Table [S1](#SM1){ref-type="supplementary-material"}.

Analysis of Binding Interaction Between Tachyplesin and FabG Protein
--------------------------------------------------------------------

N-terminal His-tagged FabG from *E. coli* and C-terminal His-tagged FabG from *Staphylococcus aureus* were cloned into the NcoI and XhoI cloning sites of the vector pET28a, expressed in BL21 DE3 *E. coli* and further purified with Ni resin ([@B26]; [@B55]). The binding interaction between tachyplesin III and FabG was analyzed by surface plasmon resonance (SPR) with a Biocore 3000 (Biocore, Piscataway, NJ, United States). Briefly, tachyplesin III was adsorbed onto a CM5 sensor chip using an amine-coupling kit (GE Healthcare, Little Chalfont, United Kingdom) to obtain approximately 1000 resonance units. For the analysis, different concentrations of FabG proteins in running buffer (HBS-N buffer, GE Healthcare) were injected at a flow rate of 20 μl/min for 6 min. The binding affinity of FabG for tachyplesin III was determined by BIAevaluation 3.0 software (Biacore) with a 1:1 Langmuir binding model for the kinetic calculation ([@B58]).

FabG Enzyme Activity Inhibition Assay
-------------------------------------

A 96-well plate with a final total volume of 200 μl per reaction was used for the FabG inhibition assay. Briefly, tachyplesin III (15, 7.5, and 3.75 μM) was incubated with 1.5 μM FabG from *E. coli* or 6 μM FabG from *S. aureus* at room temperature for 5 min, before the addition of 300 μM nicotinamide adenine dinucleotide phosphate (NADPH, Sigma) and then 150 μM acetoacetyl-CoA (Sigma) to initiate the reaction. The decrease in absorbance at 340 nm was recorded over 5 min to reflect the consumption of NADPH.

Molecular Docking Prediction
----------------------------

Tachyplesin III was processed with Chemdraw 11.0 according to the structure of tachyplesin I (PDB code 2RTV) and docked to the active site of FabG from *E. coli* (PDB code 1Q7B) or *Staphylococcus aureus* (PDB code 3SJ7) with AutoDock4 using the default settings ([@B49]; [@B41]; [@B11]; [@B27]).

Results
=======

Tachyplesin III Was Stable in Mouse Serum
-----------------------------------------

Tachyplesin III was stable after incubation in sterile deionized water at 37°C for nearly 48 h, reflected by the fact that the MIC against DH5α increased slightly from 4 mg/L to 8 mg/L after 24 h of incubation. A similar phenomenon was observed when tachyplesin III was incubated with mouse serum, which was tested during the first 6 h (**Figure [1](#F1){ref-type="fig"}**).

![Serum stability of tachyplesin III. Tachyplesin III (2 mg/ml) was incubated in either sterile deionized water or mouse serum at 37°C for various lengths of time, aliquots were taken, and MICs against DH5α cells were tested. Stability of the MIC indicates the stability of tachyplesin III.](fmicb-09-00825-g001){#F1}

Tachyplesin Was Cytotoxic to Mammalian Cells at High Concentrations
-------------------------------------------------------------------

Approximately 1% and 2% hemolysis was observed when tachyplesin III was applied at concentrations of 50 and 100 mg/L, respectively, and hemolysis accelerated as the concentration of tachyplesin increased further (**Figure [2A](#F2){ref-type="fig"}**). Cell viability of L919 cells, the murine fibroblast cell line used for toxicity testing, declined sharply when the concentration of tachyplesin increased from 50 mg/L to 100 mg/L (**Figure [2B](#F2){ref-type="fig"}**). Dramatic decreases in viability were observed in 293FT human embryonic kidney cells when tachyplesin was increased from 100 mg/L to 200 mg/L (**Figure [2C](#F2){ref-type="fig"}**) and in A549 adenocarcinomic human alveolar basal epithelial cells when tachyplesin was increased 200 mg/L to 400 mg/L (**Figure [2D](#F2){ref-type="fig"}**).

![Cytotoxicity of tachyplesin III. Cytotoxicity of tachyplesin III was tested by hemolysis and cell viability assays. **(A)** Tachyplesin III dissolved in 0.9% saline was added to mouse erythrocytes that were diluted with the same buffer. After 30 min of incubation at 37°C and then centrifugation at 1000 *g* for 15 min, supernatants were diluted 1:4 with 0.9% saline, and absorbance at 540 nm was tested. With 1% Triton X-100 (v/v) to determine 100% hemolysis and 0.9% saline as the negative control, the hemolysis rate was calculated as \[(Absorbance~sample~^-^Absorbance~control~)/(Absorbance~100%~^-^Absorbance~control~)\] × 100. Cytotoxicity was assessed using the Cell Proliferation Kit II (XTT) (Roche) for **(B)** L929 (mouse fibroblast cell line), **(C)** 293FT (human embryonic kidney cell line) and **(D)** A549 (adenocarcinomic human alveolar basal epithelial cell line) cells. Absorbance \[A492-A690 nm\] was used to quantify viable cells.](fmicb-09-00825-g002){#F2}

Effect of Tachyplesin on Pathogens at Low and High Concentrations
-----------------------------------------------------------------

PI is a DNA-binding fluorescent dye that can penetrate broken membranes but not intact membranes. As shown in **Figure [3](#F3){ref-type="fig"}**, while levofloxacin at low concentrations (1/4× MIC) did not affect the integrity of bacterial membranes, some of the bacterial membranes were broken slightly after treatment with levofloxacin at 4× MIC for 1 h at 25°C, as indicated by the emergence of weak red PI fluorescence inside these cells. Interestingly, tachyplesin at low concentrations (1/4× MIC) could also induce slight membrane breakage in a small proportion of the treated bacteria, while tachyplesin at high concentrations induced complete membrane breakage of nearly all of the treated bacteria.

![Propidium iodide staining after treatment with levofloxacin or tachyplesin III at different concentrations. First, 1 × 10^7^ MDR clinical isolates of *P. aeruginosa* strain 1409 were incubated with 1/4× MIC (4 μg/ml), 4× MIC (64 μg/ml) levofloxacin (Tokyo Chemical Industry Co. Ltd) or 1/4× MIC (2 μg/ml), 4× MIC (32 μg/ml) tachyplesin III in Luria-Bertani (LB) medium at 25°C for 1 h. After centrifugation at 3000 *g* for 10 min, cells were resuspended in the same volume of PBS (phosphate-buffered saline, 8 g/L NaCl, 0.2 g/L KCl, 1.44 g/L Na~2~HPO~4~, 0.24 g/L KH~2~PO~4~, pH 7.4). Then, PI was added to a final concentration of 10 μg/ml. After 30 min of incubation at 25°C, the cells were washed three times with PBS and immediately imaged with a fluorescence microscope.](fmicb-09-00825-g003){#F3}

Confocal laser-scanning microscopy showed more detailed results (**Figure [4](#F4){ref-type="fig"}**). After treatment with 1/4× MIC at 25°C for 1 h, most of the FITC-tagged tachyplesin (green in **Figure [4F](#F4){ref-type="fig"}**, left) co-localized with DNA (stained blue by Hoechst in **Figure [4H](#F4){ref-type="fig"}**, left) rather than with bacterial membranes (stained red by SynaptoRed C2 in **Figure [4S](#F4){ref-type="fig"}**, left). Treatment with tachyplesin at 4× MIC showed completely different results: tachyplesin was dispersed all over the bacteria (**Figure [4F](#F4){ref-type="fig"}**, right), including nuclear regions (**Figure [4H](#F4){ref-type="fig"}**, right) and bacterial membranes (**Figure [4S](#F4){ref-type="fig"}**, right). Notably, bacteria treated with tachyplesin at 4× MIC showed marked shape changes, including elongated nuclear regions (**Figure [4H](#F4){ref-type="fig"}**, right vs. **Figure [4H](#F4){ref-type="fig"}**, left) and enlarged cell bodies (**Figure [4S](#F4){ref-type="fig"}** right vs. **Figure [4S](#F4){ref-type="fig"}** left).

![Localization of tachyplesin III with confocal laser-scanning microscopy. First, 1 × 10^7^ MDR clinical isolates of *A. baumannii* strain 1408 were incubated with 1/4× MIC (2 μg/ml) or 4× MIC (32 μg/ml) N-terminally tagged tachyplesin III in LB medium at 25°C for 1 h. After centrifugation at 3000 *g* for 10 min, cells were resuspended with the same volume PBS and incubated with 20 μg/ml Hoechst (Sigma) at room temperature for 20 min. After another centrifugation at 3000 *g* for 10 min, cells were resuspended with the same volume of Hank's solution (8 g/L NaCl, 0.4 g/L KCl, 1 g/L glucose, 60 mg/L KH~2~PO~4~, 47.5 mg/L Na~2~HPO~4~, pH 7.2) and incubated with 20 μg/ml SynaptoRed C2 (Tocris Bioscience) on ice for 1 min. Confocal laser-scanning microscopy was performed with excitation and emission wavelengths, respectively, of 488 nm and 530 nm for FITC, 352 nm and 461 nm for Hoechst, and 515 and 640 nm for SynaptoRed C2.](fmicb-09-00825-g004){#F4}

Pathways for the Biosynthesis of Unsaturated Fatty Acids Were Altered in All of the Pathogens Treated With Tachyplesin but Not Levofloxacin
-------------------------------------------------------------------------------------------------------------------------------------------

The raw sequence data reported in this paper have been deposited in the Genome Sequence Archive at the Beijing Institute of Genomics, Chinese Academy of Sciences, under accession number [CRA000801](CRA000801) and are publicly accessible at <http://bigd.big.ac.cn/gsa> ([@B57]; [@B4]). Unique read numbers for each expressed gene were calculated using FPKM and are shown in Supplementary Data Sheet [S1](#SM3){ref-type="supplementary-material"}. Fold changes of expressed genes and corresponding *p*-values are shown in Supplementary Data Sheet [S2](#SM4){ref-type="supplementary-material"}.

Among all of the KEGG pathways shared in all of the pathogens subjected to transcriptional analysis after tachyplesin treatment, the "biosynthesis of unsaturated fatty acids" pathway (KEGG ID 01040) was not enriched in any of the pathogens treated with levofloxacin (**Table [1](#T1){ref-type="table"}**). Although the geraniol degradation pathway (KEGG ID 00281) was detected in the transcriptional analysis of tachyplesin-treated pathogens and undetected in levofloxacin-treated pathogens, such transcriptional changes were not shared by all of the pathogens tested, and this pathway was excluded from further analysis. The nicotinate and nicotinamide metabolism pathway, which was shared among all of the pathogens subjected to transcriptional analysis (and verified on the proteomic level based on unpublished data) after tachyplesin treatment, was excluded for similar reasons. Though transcriptional changes in this pathway were not detected after levofloxacin treatment, this pathway was affected at the proteomic level after levofloxacin treatment in both of the pathogens tested (*A. baumannii* 1408 and *P. aeruginosa* 1409, in unpublished data).

###### 

Affected KEGG pathways shared among Ta-treated pathogens after transcriptome analysis and their existence in Lvf-treated pathogens.

  KEGG ID   Terms shared                                   *P*~min~    Detected in Lvf-treated pathogens
  --------- ---------------------------------------------- ----------- -----------------------------------
  00281     Geraniol degradation (Kp-)^a^                  0.000142    --
  00280     Valine, leucine, and isoleucine degradation    0.005811    \+
  00071     Fatty acid degradation                         0.0099055   \+
  01212     Fatty acid metabolism                          0.0045136   \+
  01040     Biosynthesis of unsaturated fatty acids        0.070313    --
  00380     Tryptophan metabolism                          0.0868888   \+
  00362     Benzoate degradation                           0.0951633   \+
  00310     Lysine degradation                             0.1114944   \+
  00410     beta-Alanine metabolism (Ab-)^b^               0.135456    \+
  00760     Nicotinate and nicotinamide metabolism         0.0011823   --
  00230     Purine metabolism                              0.1948386   \+
  00270     Cysteine and methionine metabolism (Ab-)^b^    0.0055591   \+
  00640     Propanoate metabolism                          0.083494    \+
  00650     Butanoate metabolism                           0.128707    \+
  01110     Biosynthesis of secondary metabolites          0.1493282   \+
  00240     Pyrimidine metabolism (Ab-)^b^                 0.4485617   \+
  01200     Carbon metabolism                              0.1854894   \+
  01230     Biosynthesis of amino acids (Ab-)^b^           0.55726     \+
  01120     Microbial metabolism in diverse environments   0.0306      \+
  01100     Metabolic pathways                             0.27439     \+
  02020     Two-component system                           0.04481     \+

KEGG, Kyoto Encyclopedia of Genes and Genomes; Pmin, minimum

P

-value detected; Ta, tachyplesin III; Lvf, levofloxacin; Ab,

A. baumannii

; Kp, K.

pneumoniae

. -, undetected; +, detected;

a

undetected in

K. pneumoniae

;

b

undetected in

A. baumannii

.

Expression of *FabG*, Part of the Unsaturated Fatty Acid Biosynthetic Pathway, Was Elevated After Tachyplesin Treatment in All Pathogens Tested
-----------------------------------------------------------------------------------------------------------------------------------------------

Supplementary Figure [S1](#SM5){ref-type="supplementary-material"} shows details of the biosynthetic pathways for unsaturated fatty acids of all the bacteria tested. Notably, the *FabG* gene, which encodes 3-ketoacyl-acyl carrier protein reductase, was the only gene with elevated expression detected after tachyplesin III treatment in all four bacteria (**Table [2](#T2){ref-type="table"}**). These elevations after tachyplesin III treatment were also confirmed by quantitative real-time PCR (**Figure [5](#F5){ref-type="fig"}**).

###### 

Differentially expressed genes in the biosynthesis of unsaturated fatty acids pathways after treatment.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Bacteria   Gene ID        FPKM    Fold change after Ta treatment   *P* value after Ta treatment   Description               
  ---------- -------------- ------- -------------------------------- ------------------------------ ------------- ----------- --------------------------------------------
  Ab         A1S_2061       323     328                              891                            2.89          7.42E-79    3-ketoacyl-acyl carrier protein reductase

  Ec         b1093\         633\    627\                             715\                           1.11\         0.057\      3-ketoacyl-acyl carrier protein reductase\
             b3846          97      94                               260                            2.3           9.78E-39    3-hydroxyacyl-CoA dehydrogenase

  Kp         KPNJ2_03426\   41.4\   80.6\                            69\                            1.83\         0.02\       3-ketoacyl-acyl carrier protein reductase\
             KPNJ2_01584    128     190                              237                            2             3.04E-17    Enoyl-CoA hydratase

  Pa         PADK2_25405\   56\     43\                              160\                           2.71\         4.51E-17\   3-ketoacyl-acyl carrier protein reductase\
             PADK2_09275    361     369                              774                            2.04          5.71E-74    3-hydroxyacyl-CoA dehydrogenase
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Ab,

A. baumannii

; Ec,

E. coli

; Kp,

K. pneumoniae

; Pa,

P. aeruginosa

; FPKM, expected number of fragments per kilobase of transcript sequence per millions of base pairs sequenced; Ta, tachyplesin III; Lvf, levofloxacin.

![Expression of *FabG* increased after tachyplesin treatment. Quantitative real-time PCR was performed following the 2^-ΔΔCT^ method. Untreated pathogen strains were used as the calibrator strains, and the corresponding ribosomal *rpsL* genes were used as housekeeping reference gene with the primers shown in Supplementary Table [S1](#SM1){ref-type="supplementary-material"}.](fmicb-09-00825-g005){#F5}

RNA-Silencing of *FabG* Reduced Bacterial Colony Counts
-------------------------------------------------------

As shown in **Figure [6A](#F6){ref-type="fig"}**, three of the RNA oligos (1259, 1768, and 1430) that we selected worked well and significantly down-regulated the expression of *FabG* in *P. aeruginosa* (*p* \< 0.01), which was accompanied by reduced bacterial colony survival (**Figure [6B](#F6){ref-type="fig"}**). However, for RNA oligo 1534, which was inefficient at down-regulating *FabG* in *P. aeruginosa*, transformation of this RNA oligo had no effect on the survival rate of bacterial colonies.

![RNA silencing of *FabG* reduced bacterial colony counts. Using the RNA oligo pairs shown in Supplementary Table [S2](#SM2){ref-type="supplementary-material"} (GenePharma Co., Ltd, Shanghai, China) to target *FabG* from *P. aeruginosa*, RNAi was carried out with a GenePulser Xcell system using a 2 mm cuvette with the default settings for electrotransformation-competent *P. aeruginosa* cells (2.5 kV/cm, 25 μF and 200 Ω). The transformants were either spread onto LB agar plates to calculate bacterial clones **(B)** or incubated in LB medium at 37°C for 40 min to determine *FabG* transcripts by RT-PCR **(A)** with the primers for *P. aeruginosa* shown in Supplementary Table [S1](#SM1){ref-type="supplementary-material"}. Statistical significance was analyzed by one-way ANOVA followed by the Newman--Keuls multiple-comparisons test, ^∗∗^*p* \< 0.01, ^∗^*p* \< 0.05.](fmicb-09-00825-g006){#F6}

Tachyplesin III Binding With FabG Inhibited Its Enzyme Activities *in Vitro*, Likely by Blocking the Active Site
----------------------------------------------------------------------------------------------------------------

Surface plasmon resonance analysis showed that tachyplesin III could bind with FabG from *E. coli* (**Figure [7A](#F7){ref-type="fig"}**) or *S. aureus* (**Figure [7E](#F7){ref-type="fig"}**) in a dose-dependent manner. This binding interaction between tachyplesin III and FabG is accompanied by inhibition of the enzyme activities of FabG (**Figures [7B,F](#F7){ref-type="fig"}**). While FabG from *E. coli* consumed 54% of NADPH after incubation for 5 min at room temperature, incubation with 15, 7.5 and 3.75 μM tachyplesin III reduced the consumption rates to 22, 29, and 34%, respectively (**Figure [7B](#F7){ref-type="fig"}**). The tests with FabG from *S. aureus* showed even more marked results. While FabG from *S. aureus* consumed 42% of NADPH after 5 min of incubation at room temperature, only 4% of NADPH was consumed after incubation with 3.75 μM tachyplesin III, and FabG activity was almost completely blocked after incubation with higher concentrations of tachyplesin III (**Figure [7F](#F7){ref-type="fig"}**).

![Tachyplesin III binding with FabG inhibits its enzyme activities *in vitro*, probably by blocking the active site. Binding interactions between tachyplesin III and FabG from *E. coli* **(A)** or from *S. aureus* **(E)** were analyzed by surface plasmon resonance (SPR) with a Biocore 3000 (Biocore, Piscataway, NJ, United States). Black line: 1.25 μg/mL FabG; green line: 2.5 μg/mL FabG; purple line: 5 μg/mL FabG; and red line: 10 μg/mL FabG. The inhibitory activity of tachyplesin III on FabG from *E. coli* **(B)** or from *S. aureus* **(F)** was evaluated based on the remaining NADPH (which shows absorbance at 340 nm at 𝜀~340~ = 6.3 × 10^3^ mol^-1^) after FabG consumption for 5 min at room temperature. Tachyplesin was processed with Chemdraw 11.0 according to the structure of tachyplesin I (PDB code 2RTV) and then docked to the active site of FabG from *E. coli* (PDB code 1Q7B) or *S. aureus* (PDB code 3SJ7) with AutoDock4 using the default settings. Docking of tachyplesin III into *E. coli* is shown in **(C)**, docking details are shown in **(D)**. Docking of tachyplesin III into *S. aureus* is shown in **(G)**, docking details are shown in **(H)**. In **(C,G)**, tachyplesin III is shown in green, and NADPH is shown in red. Statistical significance was analyzed by one-way ANOVA followed by the Newman--Keuls multiple-comparisons test, ^∗∗^*p* \< 0.01, ^∗^*p* \< 0.05.](fmicb-09-00825-g007){#F7}

As tachyplesin III could bind with FabG and inhibit its enzyme activities, we next predicted whether tachyplesin III could block the active site of FabG. Molecular docking analysis results showed that tachyplesin III could fit into the substrate-binding region of FabG proteins from both *E. coli* (**Figure [7C](#F7){ref-type="fig"}**) and *S. aureus* (**Figure [7G](#F7){ref-type="fig"}**), which is consistent with its efficacy against both Gram-negative and Gram-positive bacteria. Detailed analysis showed that tachyplesin could interact with the active site of FabG via hydrophobic interactions and van der Waals forces. Tachyplesin interacted with R15, N145, Y151, A152, N40, D92, and F183 and formed hydrogen bonds with N40, D92, N145, and Q148 in the active site of *E. coli* FabG (**Figure [7D](#F7){ref-type="fig"}**); in *S. aureus*, it interacted with K39, R92, D93, L96, P147, Y152, K198, and Q200 and formed hydrogen bonds with Leu96, Thr190, and Gln200 in the active site (**Figure [7H](#F7){ref-type="fig"}**).

Discussion
==========

Since the discovery of tachyplesin approximately 30 years ago, its potential and broad-spectrum activities against MDR bacteria have been repeatedly confirmed ([@B43]). Though experimental induction of resistance to tachyplesin was reported recently in Gram-negative bacteria, with the resistance mechanism of *P. aeruginosa* "not entirely dependent on extracellular proteolytic degradation of tachyplesin," this resistance ability quickly disappeared after 6--9 passages without tachyplesin pressure because maintaining resistance may be a huge cost, similar to resistance to colistin ([@B15]; [@B20]). Moreover, our results showed that tachyplesin III was stable in mouse serum for at least 6 h (**Figure [1](#F1){ref-type="fig"}**). As mouse serum is enriched in endogenous mammalian proteases, these results demonstrated that tachyplesin was resistant to proteolysis and may be stable *in vivo*.

Compared with serum stability issues, cytotoxicity seems to be the real inherent defect hindering the clinical application of tachyplesin ([@B13]). At a final concentration of 100 mg/L, tachyplesin caused lysis of approximately 2% of hemocytes (**Figure [2A](#F2){ref-type="fig"}**), as well as a decline in the cell viability of 293FT human embryonic kidney cells (**Figure [2C](#F2){ref-type="fig"}**) and a sharp decline in the cell viability of L919 murine fibroblasts (**Figure [2B](#F2){ref-type="fig"}**), a cell line commonly used for toxicity testing. Interestingly, tumor cells such as A549 adenocarcinomic human alveolar basal epithelial cells seem to be more resistant to tachyplesin (**Figure [2D](#F2){ref-type="fig"}**), which made the reports of its anticancer effects somewhat controversial ([@B14]; [@B31]).

A deep understanding of how tachyplesin works may help in developing novel effective antibiotics based on similar mechanisms while avoiding the problematic cytotoxicity. Compared with the DNA binding theory, the membrane rupture theory seems to be more likely as bacterial membrane rupture is an obvious phenomenon after tachyplesin treatment at both lethal and sublethal concentrations (**Figure [3](#F3){ref-type="fig"}**). It is natural to deduce that tachyplesin may act directly on membranes and form leakage pores to kill bacteria, and numerous studies have focused on the direct interactions between tachyplesin and membranes, mainly using artificial lipid bilayers ([@B39]; [@B7]; [@B18]). Interestingly, these studies have found that linear analogs of tachyplesin without disulfides also possess the membrane disruptive abilities of original tachyplesin but translocate through these bilayers inefficiently and accompanied by weaker antibacterial activities, implying that membrane translocation abilities instead of direct membrane rupture abilities are vital for its antibacterial activity ([@B39]). Furthermore, PEGylation of tachyplesin did not alter the toroidal pore formation and membrane translocation activities of tachyplesin but reduced its cytotoxicity and antimicrobial activities, implying that events inside the cell may determine both the cytotoxicity and the antimicrobial activities of tachyplesin ([@B22]).

Proteomic profiling showed that low concentrations of tachyplesin may promote apoptosis in the glioblastoma multiforme cell line U251 by affecting intracellular enzymes and cause cell death in *E. coli* by inactivating intracellular esterases ([@B20]; [@B31]). However, treatment with a high concentration of tachyplesin caused the rapid death of K562 human erythroleukemia cells and *E. coli*, accompanied by complete cell membrane rupture in both cases ([@B46]; [@B20]). This phenomenon was also observed in our studies, in which sublethal concentrations of tachyplesin aggregated at specific regions within bacteria (**Figure [4](#F4){ref-type="fig"}**, 1/4× MIC) and caused slight membrane rupture in a small proportion of the bacteria (**Figure [3](#F3){ref-type="fig"}**, 1/4× MIC), whereas a lethal concentration of tachyplesin dispersed all over the bacteria (**Figure [4](#F4){ref-type="fig"}**, 4× MIC) and caused complete membrane rupture in nearly all of the treated bacteria (**Figure [3](#F3){ref-type="fig"}**, 4× MIC).

Two phenomena should be noted among these results. First, only some of the bacteria treated with lethal concentrations of levofloxacin showed membrane rupture, and the membrane rupture was minor in most cases, as demonstrated by the limited entrance of PI into treated bacteria and the weak fluorescent signals detected (**Figure [3](#F3){ref-type="fig"}**, 4× MIC for levofloxacin). As levofloxacin is known to disturb DNA separation and supercoiling by inhibiting bacterial topoisomerases, thereby killing the cells, the slight membrane rupture is presumably the result of cell death ([@B9]; [@B16]). By contrast, nearly all the bacteria treated with lethal concentrations of tachyplesin showed bright fluorescent signals (**Figure [3](#F3){ref-type="fig"}**, 4× MIC for tachyplesin), demonstrating that all of the bacteria killed by tachyplesin showed thorough membrane rupture and thus indicating that tachyplesin likely kills bacteria by targeting the membrane. To our surprise, existing theories concerning this topic are mainly based on the depiction of the physical interactions between this peptide and artificial lipid bilayers, and few biological details are offered. A dual effect theory emerged recently, suggesting that tachyplesin enter bacteria via the formation of non-lethal membrane pores, cause sub-lethal effects at low concentrations by inactivating intracellular enzymes, and cause cell membrane disruption at high concentrations. It may be difficult for a peptide to perform so many functions to kill bacteria, and some of those functions are unnecessary because they are not lethal. Moreover, no further biological details concerning membrane rupture have been reported ([@B46]; [@B20]). Second, bacteria treated with lethal concentrations of tachyplesin showed elongated nuclear regions (**Figure [4H](#F4){ref-type="fig"}**, right vs. **Figure [4H](#F4){ref-type="fig"}**, left) and enlarged cell bodies (**Figure [4S](#F4){ref-type="fig"}**, right vs. **Figure [4S](#F4){ref-type="fig"}**, left). This phenomenon was revealed by an approach called bacterial cytological profiling (BCP) that is quite helpful for characterizing the action mechanisms of antibiotics ([@B44]). Though membrane lengths and DNA lengths of bacteria treated with lethal concentrations of tachyplesin were approximately twice those of bacteria treated with sublethal concentrations, which is consistent with the lipid biosynthesis inhibitors reported in this paper, we have no corresponding models or exact parameters for determining the mechanism of action with the BCP method.

As our laboratory could not conduct the BCP analysis, we turned to omics techniques to identify the effects of tachyplesin treatment on bacteria and to elucidate its action mechanisms ([@B25]; [@B50]). Compared with levofloxacin-treated bacteria, all of the pathogens treated with tachyplesin III showed marked effects on the biosynthesis of unsaturated fatty acids, which is important for membrane fluidity, and this result was verified at the protein level (**Table [1](#T1){ref-type="table"}**). In this pathway, the β-ketoacyl-acyl carrier protein (ACP) reductase FabG was up-regulated in all the bacteria tested (**Figure [5](#F5){ref-type="fig"}** and **Table [2](#T2){ref-type="table"}**). RNA silencing of *FabG* showed that efficient silencing of *FabG* by RNA oligos (**Figure [6A](#F6){ref-type="fig"}**) is accompanied by the reduced survival of bacterial colonies (**Figure [6B](#F6){ref-type="fig"}**), which is consistent with previous reports that *FabG* is a conserved and essential gene in various bacteria such that knockout of this enzyme results in bacterial death ([@B60]; [@B28]; [@B3]; [@B47]; [@B6]).

The biosynthesis of unsaturated fatty acids occurs in the cytoplasm, and the membrane translocation activities of tachyplesin accompany its antimicrobial activities. *FabG* is essential for the growth of bacteria, and inhibition of FabG is associated with antimicrobial activity in both *E. coli* and *S. aureus* ([@B54]). Thus, we propose that tachyplesin may kill bacteria by inhibiting FabG activities. Our surface plasmon resonance analysis results showed that tachyplesin III could bind with FabG from *E. coli* (**Figure [7A](#F7){ref-type="fig"}**) and *S. aureus* (**Figure [7E](#F7){ref-type="fig"}**) in a dose-dependent manner. This binding interaction between tachyplesin III and FabG is accompanied by inhibition of the enzyme activities of FabG (**Figures [7B,F](#F7){ref-type="fig"}**). Molecular docking predictions showed that tachyplesin III could not only enter the active site of FabG from *E. coli* by hydrophobic interactions and van der Waals forces but also block the NADPH binding site by interacting with the corresponding amino acid residues and forming stable hydrogen bonds (**Figures [7C,D](#F7){ref-type="fig"}**). A similar phenomenon was observed for the interaction of tachyplesin III and Gram-positive *S. aureus* (**Figures [7G,H](#F7){ref-type="fig"}**), which is consistent with the broad antimicrobial spectrum of tachyplesin.

Many antibiotics targeting bacterial pathways for fatty acid biosynthesis show some cytotoxicity to mammalian cells. For example, triclosan can kill bacteria by binding its enoyl-acyl carrier protein reductase ([@B44]), but it also shows severe hemolytic activity ([@B53]). A similar phenomenon was observed for cerulenin, which can kill bacteria by binding bacterial fatty acid synthase ([@B44]). Though no hemolytic activity was reported, cerulenin was reported to be cytotoxic to carcinoma cells ([@B48]). Whether tachyplesin III may cause toxicity to mammalian cells via similar mechanism remains to be validated. Though the fatty acid synthetic pathway in bacteria (FAS II) consists of multiple individual enzymes, whereas the fatty acid synthetic pathway in mammals (FAS I) is a single protein with multifunctional polypeptides, sequence homologies may exist at similar active sites, and inhibitors may have similar effects on both the bacterial and mammalian fatty acid synthesis pathways. These phenomena remind us that more-specific inhibitors may be selected or designed to avoid cytotoxic effects when targeting these fatty acid synthases.

Efficient entrance into cells to act on FabGs that are located in the cytoplasm may be another strategy that we should adopt from tachyplesin. It was reported that inhibitors targeting an allosteric binding site of FabG showed effects only toward Gram-positive bacteria and not toward Gram-negative *P. aeruginosa* ([@B6]). This may be attributable either to poor penetration activities of these inhibitors or to rapid efflux by *P. aeruginosa*. Though tachyplesin seems to target a different active site, designing inhibitors based on the action mechanism of tachyplesin and possessing penetration activity may be beneficial.

Conclusion
==========

We find that tachyplesin may kill bacteria by targeting FabG, the conserved β-ketoacyl-acyl carrier protein reductase in unsaturated fatty acid biosynthesis. Targeting the homologous enzyme in mammalian cells may also result in instability or rupture of cell membranes, which manifested as cytotoxicity, including hemolysis. More-detailed research concerning the structural differences between bacterial and mammalian FabG proteins, as well as the selection of more specific inhibitory ligands, may be helpful for the development of safer antibiotics designed based on the mechanism of tachyplesin.
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